Androgen modulates cardiac fibrosis contributing to gender differences on heart failure

References

• Bonneux L, Barendregt JJ, Meeter K, et al. Estimating clinical morbidity due to ischemic heart disease and congestive heart failure: the future rise of heart failure. Am J Public Health 1994;84:20–8
   PubMed Web of Science ®Google Scholar
• Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol 1993;22:6A–13A
   PubMed Web of Science ®Google Scholar
• Reitsma JB, Mosterd A, de Craen AJ, et al. Increase in hospital admission rates for heart failure in The Netherlands, 1980–1993. Heart 1996;76:388–92
   Google Scholar
• Jong P, Vowinckel E, Liu PP, et al. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch Intern Med 2002;162:1689–94
   PubMed Web of Science ®Google Scholar
• Ghali JK, Krause-Steinrauf HJ, Adams Jr.KF, et al. Gender differences in advanced heart failure: insights from the BEST study. J Am Coll Cardiol 2003;42:2128–34
   PubMed Web of Science ®Google Scholar
• Pilote L, Dasgupta K, Guru V, et al. A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ 2007;176:S1–44
   PubMed Web of Science ®Google Scholar
• Luann GR. Women and heart failure. Heart Lung 2001;30:87–97
   Google Scholar
• Malkin CJ, Pugh PJ, West JN, et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 2006;27:57–64
   PubMed Web of Science ®Google Scholar
• Pugh PJ, Jones RD, West JN, et al. Testosterone treatment for men with chronic heart failure. Heart 2004;90:446–7
   PubMed Web of Science ®Google Scholar
• Cheng S, Vasan RS. Advances in the epidemiology of heart failure and left ventricular remodeling. Circulation 2011;124:e516–9
   PubMed Web of Science ®Google Scholar
• Dobaczewski M, Frangogiannis NG. Chemokines and cardiac fibrosis. Front Biosci (Schol Ed) 2009;1:391–405
   PubMedGoogle Scholar
• Petrov VV, Fagard RH, Lijnen PJ. Stimulation of collagen production by transforming growth factor-β1 during differentiation of cardiac fibroblasts to myofibroblasts. Hypertension 2002;39:258–63
   PubMed Web of Science ®Google Scholar
• Staufenberger S, Jacobs M, Brandstätter K, et al. Angiotensin II type1 receptor regulation and differential trophic effects on rat cardiac myofibroblasts after acute myocardial infarction. J Cell Physiol 2001;187:326–35
   Google Scholar
• Li P-F, Dietz R, von Harsdorf R. Superoxide induces apoptosis in cardiomyocytes, but proliferation and expression of transforming growth factor-beta1 in cardiac fibroblasts. FEBS Lett 1999;448:206–10
   PubMed Web of Science ®Google Scholar
• Stewart JrJA, Cashatt DO, Borck AC, et al. 17β-estradiol modulation of angiotensin II-stimulated response in cardiac fibroblasts. J Mol Cell Cardiol 2006;41:97–107
   Google Scholar
• Zhou L, Shao Y, Huang Y, et al. 17β-estradiol inhibits angiotensin II-induced collagen synthesis of cultured rat cardiac fibroblasts via modulating angiotensin II receptors. Eur J Pharmacol 2007;567:186–92
   Google Scholar
• Ikeda Y, Aihara K, Yoshida S, et al. Androgen-androgen receptor system protects against angiotensin II-induced vascular remodeling. Endocrinology 2009;150:2857–64
   Google Scholar
• Ikeda Y, Aihara K, Akaike M, et al. Androgen receptor counteracts doxorubicin-induced cardiotoxicity in male mice. Mol Endocrinol 2010;24:1338–48
   Google Scholar
• Jankowska EA, Biel B, Majda J, et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation 2006;114:1829–37
   PubMed Web of Science ®Google Scholar
• Wehr E, Pilz S, Boehm BO, et al. Low free testosterone is associated with heart failure mortality in older men referred for coronary angiography. Eur J Heart Fail 2011;13:482–88
   PubMedGoogle Scholar
• Güder G, Frantz S, Bauersachs J, et al. Low circulating androgens and mortality risk in heart failure. Heart 2010;96:504–9
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, von Mühlen DG, Kritz-Silverstein D. Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study. J Clin Endocrinol Metab 1999;84:573–77
   PubMed Web of Science ®Google Scholar
• Rumsfeld JS, Havranek E, Masoudi FA, et al. Depressive symptoms are the strongest predictors of short-term declines in health status in patients with heart failure. J Am Coll Cardiol 2003;42:1811–7
   PubMed Web of Science ®Google Scholar
• Pugh PJ, Jones TH, Channer KS. Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J 2003;24:909–15
   PubMed Web of Science ®Google Scholar
• Caminiti G, Volterrani M, Iellamo F, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure: a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009;54:919–27
   PubMed Web of Science ®Google Scholar
• Iellamo F, Volterrani M, Caminiti G, et al. Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol 2010;56:1310–6
   PubMed Web of Science ®Google Scholar
• Marsh JD, Lehmann MH, Ritchie RH, et al. Androgen receptors mediate hypertrophy in cardiac myocytes. Circulation 1998;98:256–61
   PubMed Web of Science ®Google Scholar
• Altamirano F, Oyarce C, Silva P, et al. Testosterone induces cardiomyocyte hypertrophy through mammalian target of rapamycin complex 1 pathway. J Endocrinol 2009;202:299–307
   PubMedGoogle Scholar
• Sachtleben TR, Berg KE, Elias BA, et al. The effects of anabolic steroids on myocardial structure and cardiovascular fitness. Med Sci Sports Exerc 1993;25:1240–5
   Web of Science ®Google Scholar
• Urhausen A, Hölpes R, Kindermann W. One- and two-dimensional echocardiography in bodybuilders using anabolic steroids. Eur J Appl Physiol Occup Physiol 1989;58:633–40
   Web of Science ®Google Scholar
• Traish AM, Guay A, Feeley R, Saad F. The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Androl 2009;30:10–22
   PubMed Web of Science ®Google Scholar
• Traish AM, Saad F, Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl 2009;30:23–32
   PubMedGoogle Scholar
• Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med 1992;117:807–11
   PubMed Web of Science ®Google Scholar
• Barud W, Palusiński R, Bełtowski J, Wójcicka G. Inverse relationship between total testosterone and anti-oxidized low density lipoprotein antibody levels in ageing males. Atherosclerosis 2002;164:283–8
   PubMed Web of Science ®Google Scholar
• Saad F, Gooren L, Haider A, Yassin A. An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Arch Androl 2007;53:353–7
   PubMed Web of Science ®Google Scholar
• Saad F, Gooren LJ, Haider A, Yassin A. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl 2008;29:102–5
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab 2007;92:3844–53
   PubMed Web of Science ®Google Scholar
• Zgliczynski S, Ossowski M, Slowinska-Srzednicka J, et al. Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis 1996;121:35–43
   PubMed Web of Science ®Google Scholar
• Uyanik BS, Ari Z, Gümüs B, et al. Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men: a placebo controlled study. Jpn Heart J 1997;38:73–82
   PubMedGoogle Scholar
• Thompson PD, Cullinane EM, Sady SP, et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 1989;261:1165–8
   PubMed Web of Science ®Google Scholar
• Bagatell CJ, Heiman JR, Matsumoto AM, et al. Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. J Clin Endocrinol Metab 1994;79:561–7
   PubMed Web of Science ®Google Scholar
• Traish AM, Abdou R, Kypreos KE. Androgen deficiency and atherosclerosis: the lipid link. Vascul Pharmacol 2009;51:303–3
   PubMed Web of Science ®Google Scholar
• Weber K, Janicki J, Shroff S, et al. Collagen remodeling of the pressure-overloaded, hypertrophied nonhuman primate myocardium. Circ Res 1988;62:757–65
   PubMed Web of Science ®Google Scholar
• Laviades C, Varo N, Fernández J, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998;98:535–40
   PubMed Web of Science ®Google Scholar
• Factor SM, Robinson TF, Dominitz R, Cho SH. Alterations of the myocardial skeletal framework in acute myocardial infarction with and without ventricular rupture: a preliminary report. Am J Cardiovasc Pathol 1987;1:91–7
   Google Scholar
• Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000;101:2981–8
   PubMed Web of Science ®Google Scholar
• Erlebacher JA, Weiss JL, Weisfeldt ML, Bulkley BH. Early dilation of the infarcted segment in acute transmural myocardial infarction: role of infarct expansion in acute left ventricular enlargement. J Am Coll Cardiol 1984;4:201–8
   PubMed Web of Science ®Google Scholar
• Cleutjens JP, Kandala JC, Guarda E, et al. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 1995;27:1281–92
   PubMed Web of Science ®Google Scholar
• Sadoshima J, Jahn L, Takahashi T, et al. Molecular characterization of the stretch-induced adaptation of cultured cardiac cells: an in vitro model of load-induced cardiac hypertrophy. J Biol Chem 1992;267:10551–60
   PubMed Web of Science ®Google Scholar
• Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest 2007;117:568–75
   PubMed Web of Science ®Google Scholar
• Weber KT, Pick R, Jalil JE, et al. Patterns of myocardial fibrosis. J Mol Cell Cardiol 1989;21:121–31
   PubMedGoogle Scholar
• Weber KT. Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 1989;13:1637–52
   PubMed Web of Science ®Google Scholar
• Diez J, Hernandez M. Is the extracellular degradation of collagen type I fibers depressed in spontaneously hypertensive rats with myocardial fibrosis? Circulation 1996;94:2998
   Google Scholar
• Díez J, Panizo A, Gil MJ, et al. Serum markers of collagen type I metabolism in spontaneously hypertensive rats: relation to myocardial fibrosis. Circulation 1996;93:1026–32
   PubMed Web of Science ®Google Scholar
• Norton GR, Tsotetsi J, Trifunovic B, et al. Myocardial stiffness is attributed to alterations in cross-linked collagen rather than total collagen or phenotypes in spontaneously hypertensive rats. Circulation 1997;96:1991–8
   PubMed Web of Science ®Google Scholar
• Gordon EE, Kira Y, Demers LM, Morgan HE. Aortic pressure as a determinant of cardiac protein degradation. Am J Physiol 1986;250:C932–8
   PubMed Web of Science ®Google Scholar
• Morgan HE, Siehl D, Chua BH, Lautensack-Belser N. Faster protein and ribosome synthesis in hypertrophying heart. Basic Res Cardiol 1985;80:115–8
   Google Scholar
• Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Circulation 2000;102:2700–6
   PubMed Web of Science ®Google Scholar
• Uusimaa P, Risteli J, Niemelä M, et al. Collagen scar formation after acute myocardial infarction: relationships to infarct size, left ventricular function, and coronary artery patency. Circulation 1997;96:2565–72
   PubMed Web of Science ®Google Scholar
• Díez J. Mechanisms of cardiac fibrosis in hypertension. J Clin Hypertens (Greenwich) 2007;9:546–50
   PubMedGoogle Scholar
• Leask A. Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res 2010;106:1675–80
   PubMed Web of Science ®Google Scholar
• Kane CJ, Hebda PA, Mansbridge JN, Hanawalt PC. Direct evidence for spatial and temporal regulation of transforming growth factor beta 1 expression during cutaneous wound healing. J Cell Physiol 1991;148:157–73
   PubMedGoogle Scholar
• Schiller M, Javelaud D, Mauviel A. TGF-beta-induced SMAD signaling and gene regulation: consequences for extracellular matrix remodeling and wound healing. J Dermatol Sci 2004;35:83–92
   PubMed Web of Science ®Google Scholar
• Mauviel A. Transforming growth factor-beta: a key mediator of fibrosis. Methods Mol Med 2005;117:69–80
   PubMedGoogle Scholar
• Desmoulière A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 1993;122:103–11
   PubMed Web of Science ®Google Scholar
• LeRoy EC, Trojanowska MI, Smith EA. Cytokines and human fibrosis. Eur Cytokine Netw 1990;1:215–9
   PubMedGoogle Scholar
• Verrecchia F, Mauviel A. Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol 2002;118:211–5
   PubMed Web of Science ®Google Scholar
• Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999;79:215–62
   PubMed Web of Science ®Google Scholar
• Porter KE, Turner NA. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 2009;123:255–78
   PubMed Web of Science ®Google Scholar
• Campbell SE, Katwa LC. Angiotensin II stimulated expression of transforming growth factor-beta1 in cardiac fibroblasts and myofibroblasts. J Mol Cell Cardiol 1997;29:1947–58
   PubMed Web of Science ®Google Scholar
• Schultz JEJ, Witt SA, Glascock BJ, et al. TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 2002;109:787–96
   Google Scholar
• Zatelli MC, Rossi R, degli Uberti EC. Androgen influences transforming growth factor-beta1 gene expression in human adrenocortical cells. J Clin Endocrinol Metab 2000;85:847–52
   Google Scholar
• Evangelou A, Jindal SK, Brown TJ, Letarte M. Down-regulation of transforming growth factor beta receptors by androgen in ovarian cancer cells. Cancer Res 2000;60:929–35
   PubMed Web of Science ®Google Scholar
• Chipuk JE, Cornelius SC, Pultz NJ, et al. The androgen receptor represses transforming growth factor-beta signaling through interaction with Smad3. J Biol Chem 2002;277:1240–8
   PubMed Web of Science ®Google Scholar
• Iwasaki T, Mukasa K, Yoneda M, Ito S, et al. Marked attenuation of production of collagen type I from cardiac fibroblasts by dehydroepiandrosterone. Am J Physiol Endocrinol Metab 2005;288:E1222–8
   Google Scholar
• Ikeda Y, Aihara K, Sato T, et al. Androgen receptor gene knockout male mice exhibit impaired cardiac growth and exacerbation of angiotensin II-induced cardiac fibrosis. J Biol Chem 2005;280:29661–6
   PubMed Web of Science ®Google Scholar
• Mallat Z, Philip I, Lebret M, et al. Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation 1998;97:1536–9
   PubMed Web of Science ®Google Scholar
• McMurray J, Chopra M, Abdullah I, et al. Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J 1993;14:1493–8
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Merli E, Malagutti P, et al. Hydroxyl radical generation, levels of tumor necrosis factor-alpha, and progression to heart failure after acute myocardial infarction. J Am Coll Cardiol 2004;43:2000–8
   PubMedGoogle Scholar
• Byrne JA, Grieve DJ, Bendall JK, et al. Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy. Circ Res 2003;93:802–5
   PubMed Web of Science ®Google Scholar
• Maytin M, Siwik DA, Ito M, et al. Pressure overload-induced myocardial hypertrophy in mice does not require gp91phox. Circulation 2004;109:1168–71
   Google Scholar
• Bendall JK, Cave AC, Heymes C, et al. Pivotal role of a gp91phox-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 2002;105:293–6
   PubMed Web of Science ®Google Scholar
• Grieve DJ, Byrne JA, Siva A, et al. Involvement of the nicotinamide adenosine dinucleotide phosphate oxidase isoform Nox2 in cardiac contractile dysfunction occurring in response to pressure overload. J Am Coll Cardiol 2006;47:817–26
   PubMed Web of Science ®Google Scholar
• Johar S, Cave AC, Narayanapanicker A, et al. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J 2006;20:1546–8
   Google Scholar
• Park YM, Park MY, Suh Y-L, Park JB. NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosterone-infused rats. Biochem Biophys Res Commun 2004;313:812–7
   PubMed Web of Science ®Google Scholar
• Cucoranu I, Clempus R, Dikalova A, et al. NAD(P)H oxidase 4 mediates transforming growth factor-beta1–induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 2005;97:900–7
   PubMed Web of Science ®Google Scholar
• Bondi CD, Manickam N, Lee DY, et al. NAD(P)H oxidase mediates TGF-beta1-induced activation of kidney myofibroblasts. J Am Soc Nephrol 2010;21:93–102
   PubMed Web of Science ®Google Scholar
• Tam NNC, Gao Y, Leung YK, Ho SM. Androgenic regulation of oxidative stress in the rat prostate: involvement of NAD(P)H oxidases and antioxidant defense machinery during prostatic involution and regrowth. Am J Pathol 2003;163:2513–22
   PubMed Web of Science ®Google Scholar
• Best CJM, Gillespie JW, Yi Y, et al. Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res 2005;11:6823–34
   PubMed Web of Science ®Google Scholar
• Pang ST, Dillner K, Wu X, et al. Gene expression profiling of androgen deficiency predicts a pathway of prostate apoptosis that involves genes related to oxidative stress. Endocrinology 2002;143:4897–906
   Google Scholar
• Shan W, Zhong W, Zhao R, Oberley TD. Thioredoxin 1 as a subcellular biomarker of redox imbalance in human prostate cancer progression. Free Radic Biol Med 2010;49:2078–87
   Google Scholar
• Shiota M, Song Y, Takeuchi A, et al. Antioxidant therapy alleviates oxidative stress by androgen deprivation and prevents conversion from androgen dependent to castration resistant prostate cancer. J Urol 2012;187:707–14
   PubMed Web of Science ®Google Scholar
• Cavasin MA, Sankey SS, Yu AL, et al. Estrogen and testosterone have opposing effects on chronic cardiac remodeling and function in mice with myocardial infarction. Am J Physiol Heart Circ Physiol 2003;284:H1560–9
   PubMed Web of Science ®Google Scholar
• Cavasin MA, Tao Z, Menon S, Yang XP. Gender differences in cardiac function during early remodeling after acute myocardial infarction in mice. Life Sci 2004;75:2181–92
   Google Scholar
• Gao XM, Xu Q, Kiriazis H, et al. Mouse model of post-infarct ventricular rupture: time course, strain- and gender-dependency, tensile strength, and histopathology. Cardiovasc Res 2005;65:469–77
   Google Scholar